Cargando...
Ravulizumab: A Review in Atypical Haemolytic Uraemic Syndrome
Ravulizumab (Ultomiris(®)), a humanized monoclonal antibody that inhibits complement protein C5, is indicated for the treatment of atypical haemolytic uraemic syndrome (aHUS) in several countries, including the USA and those of the EU. Ravulizumab has been re-engineered from eculizumab to extend its...
Gardado en:
| Publicado en: | Drugs |
|---|---|
| Autor Principal: | |
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado: |
Springer International Publishing
2021
|
| Assuntos: | |
| Acceso en liña: | https://ncbi.nlm.nih.gov/pmc/articles/PMC8052220/ https://ncbi.nlm.nih.gov/pubmed/33738756 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s40265-021-01481-6 |
| Tags: |
Engadir etiqueta
Sen Etiquetas, Sexa o primeiro en etiquetar este rexistro!
|